Article
ATF4 alleviates doxorubicin-induced cardiomyopathy through H <sub>2</sub> S-mediated antioxidation
2025-09-11
Abstract excerpt
<h4>Background</h4> Doxorubicin (DOX) remains a cornerstone in the treatment of various cancers. However, its clinical utilization is significantly hampered by dose-dependent cardiotoxicity. The generation of reactive oxygen species (ROS) constitutes the central component of the pathogenesis of DOX-induced cardiotoxicity. Activating transcription factor 4 (ATF4) has been demonstrated to exert a cardioprotective e...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 657e2a95-e4e7-57ce-89e8-d814fdb69414
- DOI
- 10.1101/2025.09.03.674119
